effects of epithelial to mesenchymal transition on t cell targeting of melanoma cells.

Clicks: 167
ID: 237763
2014
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Melanoma cells can switch phenotype in a manner similar to epithelial to mesenchymal transition(EMT). In this perspective article, we address the effects of such phenotype switching on T cell targeting of tumour cells. During the EMT-like switch in phenotype, a concomitant change in expression of multiple tumour antigens occurs. Melanoma cells undergoing EMT escape from killing by T cells specific for antigens whose expression is downregulated by this process. We discuss melanoma antigens whose expression is influenced by EMT. We assess the effect of changes in the expressed tumour antigen repertoire on T cell mediated tumour recognition and killing.In addition to escape from T cell immunity via changes in antigen expression, mesenchymal-like melanoma cells are generally more resistant to classical chemotherapy and radiotherapy. However, we demonstrate that when targeting antigens whose expression is unaltered during EMT, the capacity of T cells to kill melanoma cell lines in vitro is not influenced by their phenotype. When considering immune therapies such as cancer vaccination, these data suggest escape from T cell killing due to phenotype switching in melanoma could potentially be avoided by careful selection of target antigen
Reference Key
ewoods2014frontierseffects Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Katherine eWoods;Katherine eWoods;Anupama ePasam;Anupama ePasam;Aparna eJayachandran;Aparna eJayachandran;Miles eAndrews;Miles eAndrews;Jonathan eCebon;Jonathan eCebon
Journal international journal of heat and technology
Year 2014
DOI
10.3389/fonc.2014.00367
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.